Baseline comorbidities in a skin cancer prevention trial in Bangladesh

European Journal of Clinical Investigation

Volumn 43, Issue 6, 2013, Pages 579-588

  Argos, Maria ^a   Rahman, Mahfuzar ^b   Parvez, Faruque ^c   Dignam, James ^a   Islam, Tariqul ^b   Quasem, Iftekhar ^b   K Hore, Samar ^d   T Haider, Ahmed ^b   Hossain, Zahid ^d   I Patwary, Tazul ^b   Rakibuz Zaman, Muhammad ^b   Sarwar, Golam ^b   La Porte, Paul ^a   Harjes, Judith ^e   Anton, Kristen ^e   Kibriya, Muhammad G ^a   Jasmine, Farzana ^a   Khan, Rashed ^f   Kamal, Mohammed ^g   Shea, Christopher R ^a   Yunus, Muhammad ^d   Baron, John A ^e   Ahsan, Habibul ^a   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b U Chicago Research Bangladesh Ltd   (Bangladesh)

^c Mailman School of Public Health   (United States)

^d INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f Shaheed Suhrawardy Medical College   (Bangladesh)

^g BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

Author keywords

Bangladesh; Dietary supplements; Selenium; Skin neoplasms; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ARSENIC; ORGANOARSENIC DERIVATIVE; PLACEBO; SELENOMETHIONINE;

ADULT; AGED; ARTICLE; ASTHMA; BANGLADESH; CANCER PREVENTION; CHEMOPROPHYLAXIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; KERATOSIS; MAJOR CLINICAL STUDY; MALE; NON MELANOMA SKIN CANCER; PATIENT COMPLIANCE; PEPTIC ULCER; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SKIN DEFECT;

ADULT; AGED; ALPHA-TOCOPHEROL; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; ARSENIC POISONING; BANGLADESH; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SELENOMETHIONINE; SKIN NEOPLASMS;

EID: 84877694818     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12085     Document Type: Article

References (60)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol 2006;17(Suppl. 8):viii15-23.
3. Smith AH, Lingas EO, Rahman M. Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bull World Health Organ 2000;78:1093-103.
4. Chen CJ, Chen CW, Wu MM, Kuo TL. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 1992;66:888-92.
5. Tseng WP. Effects and dose - response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 1977;19:109-19.
6. Brouwer OF, Onkenhout W, Edelbroek PM, de Kom JF, de Wolff FA, Peters AC. Increased neurotoxicity of arsenic in methylenetetrahydrofolate reductase deficiency. Clin Neurol Neurosurg 1992;94:307-10.
7. Wu MM, Kuo TL, Hwang YH, Chen CJ. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 1989;130:1123-32.
8. Rahman M, Tondel M, Ahmad SA, Chowdhury IA, Faruquee MH, Axelson O. Hypertension and arsenic exposure in Bangladesh. Hypertension 1999;33:74-8.
9. Rahman M, Tondel M, Ahmad SA, Axelson O. Diabetes mellitus associated with arsenic exposure in Bangladesh. Am J Epidemiol 1998;148:198-203.
10. Samuel S, Kathirvel R, Jayavelu T, Chinnakkannu P. Protein oxidative damage in arsenic induced rat brain: influence of DL-alpha-lipoic acid. Toxicol Lett 2005;155:27-34.
11. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med 1996;21:783-90.
12. Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci USA 1998;95:8103-7.
13. Yamanaka K, Hoshino M, Okamoto M, Sawamura R, Hasegawa A, Okada S. Induction of DNA damage by dimethylarsine, a metabolite of inorganic arsenics, is for the major part likely due to its peroxyl radical. Biochem Biophys Res Commun 1990;168:58-64.
14. Pi J, Yamauchi H, Kumagai Y, Sun G, Yoshida T, Aikawa H et al. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect 2002;110:331-6.
15. Yamauchi H, Aminaka Y, Yoshida K, Sun G, Pi J, Waalkes MP. Evaluation of DNA damage in patients with arsenic poisoning: urinary 8-hydroxydeoxyguanine. Toxicol Appl Pharmacol 2004;198:291-6.
16. Wu MM, Chiou HY, Wang TW, Hsueh YM, Wang IH, Chen CJ et al. Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ Health Perspect 2001;109:1011-7.
17. Matsui M, Nishigori C, Toyokuni S, Takada J, Akaboshi M, Ishikawa M et al. The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2'-deoxyguanosine in arsenic-related Bowen's disease. J Invest Dermatol 1999;113:26-31.
18. Tseng CH. A review on environmental factors regulating arsenic methylation in humans. Toxicol Appl Pharmacol 2009;235:338-50.
19. Andreae MO. Determination of arsenic species in natural waters. Anal Chem 1977;49:820-3.
20. Aposhian HV. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol 1997;37:397-419.
21. Le XC, Ma M, Cullen WR, Aposhian HV, Lu X, Zheng B. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ Health Perspect 2000;108:1015-8.
22. Del Razo LM, Styblo M, Cullen WR, Thomas DJ. Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 2001;174:282-93.
23. Ahmad S, Anderson WL, Kitchin KT. Dimethylarsinic acid effects on DNA damage and oxidative stress related biochemical parameters in B6C3F1 mice. Cancer Lett 1999;139:129-35.
24. Styblo M, Drobna Z, Jaspers I, Lin S, Thomas DJ. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ Health Perspect 2002;110(Suppl. 5):767-71.
25. Basu A, Mitra S, Chung J, Guha Mazumder DN, Ghosh N, Kalman D et al. Creatinine, diet, micronutrients, and arsenic methylation in West Bengal, India. Environ Health Perspect 2011;119:1308-13.
26. Hsueh YM, Ko YF, Huang YK, Chen HW, Chiou HY, Huang YL et al. Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. Toxicol Lett 2003;137:49-63.
27. Christian WJ, Hopenhayn C, Centeno JA, Todorov T. Distribution of urinary selenium and arsenic among pregnant women exposed to arsenic in drinking water. Environ Res 2006;100:115-22.
28. Chung CJ, Pu YS, Chen YT, Su CT, Wu CC, Shiue HS et al. Protective effects of plasma alpha-tocopherols on the risk of inorganic arsenic-related urothelial carcinoma. Sci Total Environ 2011;409:1039-45.
29. Wuyi W, Linsheng Y, Shaofan H, Jian'an T, Hairong L. Prevention of endemic arsenism with selenium. Curr Sci 2001;81:1215-8.
30. Yang L, Wang W, Hou S, Peterson P, Williams W. Effects of selenium supplementation on arsenism: an intervention trial in inner Mongolia. Environ Geochem Health 2002;24:359-74.
31. Ahsan H, Chen Y, Parvez F, Argos M, Hussain AI, Momotaj H et al. Health Effects of Arsenic Longitudinal Study (HEALS): description of a multidisciplinary epidemiologic investigation. J Eposure Sci Environ Epidemiol 2006;16:191-205.
32. Chen Y, Hall M, Graziano JH, Slavkovich V, van Geen A, Parvez F et al. A prospective study of blood selenium levels and the risk of arsenic-related premalignant skin lesions. Cancer Epidemiol Biomarkers Prev 2007;16:207-13.
33. Zablotska LB, Chen Y, Graziano JH, Parvez F, van Geen A, Howe GR et al. Protective effects of B vitamins and antioxidants on the risk of arsenic-related skin lesions in Bangladesh. Environ Health Perspect 2008;116:1056-62.
34. Pilsner JR, Liu X, Ahsan H, Ilievski V, Slavkovich V, Levy D et al. Genomic methylation of peripheral blood leukocyte DNA: influences of arsenic and folate in Bangladeshi adults. Am J Clin Nutr 2007;86:1179-86.
35. Pilsner JR, Hall MN, Liu X, Ahsan H, Ilievski V, Slavkovich V et al. Associations of plasma selenium with arsenic and genomic methylation of leukocyte DNA in Bangladesh. Environ Health Perspect 2011;119:113-8.
36. Verret WJ, Chen Y, Ahmed A, Islam T, Parvez F, Kibriya MG et al. A randomized, double-blind placebo-controlled trial evaluating the effects of vitamin E and selenium on arsenic-induced skin lesions in Bangladesh. J Occup Environ Med 2005;47:1026-35.
37. Kibriya MG, Jasmine F, Argos M, Verret WJ, Rakibuz-Zaman M, Ahmed A et al. Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett 2007;169:162-76.
38. Argos M, Kibriya MG, Parvez F, Jasmine F, Rakibuz-Zaman M, Ahsan H. Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population. Cancer Epidemiol Biomarkers Prev 2006;15:1367-75.
39. Hsueh YM, Cheng GS, Wu MM, Yu HS, Kuo TL, Chen CJ. Multiple risk factors associated with arsenic-induced skin cancer: effects of chronic liver disease and malnutritional status. Br J Cancer 1995;71:109-14.
40. Cabrera HN, Gomez ML. Skin cancer induced by arsenic in the water. J Cutan Med Surg 2003;7:106-11.
41. Karagas MR, Stukel TA, Morris JS, Tosteson TD, Weiss JE, Spencer SK et al. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am J Epidemiol 2001;153:559-65.
42. Pesch B, Ranft U, Jakubis P, Nieuwenhuijsen MJ, Hergemoller A, Unfried K et al. Environmental arsenic exposure from a coal-burning power plant as a potential risk factor for nonmelanoma skin carcinoma: results from a case-control study in the district of Prievidza, Slovakia. Am J Epidemiol 2002;155:798-809.
43. Leonardi G, Vahter M, Clemens F, Goessler W, Gurzau E, Hemminki K et al. Arsenic and basal cell carcinoma in areas of Hungary, Romania, and Slovakia: a case-control study. Environ Health Perspect 2012;120:721-26.
44. Marshall G, Ferreccio C, Yuan Y, Bates MN, Steinmaus C, Selvin S et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 2007;99:920-8.
45. Fernandez MI, Lopez JF, Vivaldi B, Coz F. Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure. J Urol 2012;187:856-61.
46. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR et al. Designing the selenium and vitamin E cancer prevention trial (SELECT). J Natl Cancer Inst 2005;97:94-102.
47. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010;341:c5702.
48. Demling R, Way L. Burn and other thermal injuries. In: Way LW, editor. Current Surgical Diagnosis and Treatment. Norwalk, CT: Appleton & Lange; 1994, pp 205-15.
49. 2 area of Bangladesh. Water Resour Res 2003;39:1140-55.
50. Jakariya M, Vahter M, Rahman M, Wahed MA, Hore SK, Bhattacharya P et al. Screening of arsenic in tubewell water with field test kits: evaluation of the method from public health perspective. Sci Total Environ 2007;379:167-75.
51. Hussam A, Munir AK. A simple and effective arsenic filter based on composite iron matrix: development and deployment studies for groundwater of Bangladesh. J Environ Sci Health 2007;42:1869-78.
52. Rubinstein LV, Gail MH, Santner TJ. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis 1981;34:469-79.
53. Nixon DE, Mussmann GV, Eckdahl SJ, Moyer TP. Total arsenic in urine: palladium-persulfate vs nickel as a matrix modifier for graphite furnace atomic absorption spectrophotometry. Clin Chem 1991;37:1575-9.
54. Abhyankar LN, Jones MR, Guallar E, Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 2011. Available at: http://dx.doi.org/10.1289/ehp.1103988.
55. Navas-Acien A, Silbergeld EK, Streeter RA, Clark JM, Burke TA, Guallar E. Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect 2006;114:641-8.
56. von Ehrenstein OS, Mazumder DN, Yuan Y, Samanta S, Balmes J, Sil A et al. Decrements in lung function related to arsenic in drinking water in West Bengal, India. Am J Epidemiol 2005;162:533-41.
57. Parvez F, Chen Y, Brandt-Rauf PW, Slavkovich V, Islam T, Ahmed A et al. A prospective study of respiratory symptoms associated with chronic arsenic exposure in Bangladesh: findings from the Health Effects of Arsenic Longitudinal Study (HEALS). Thorax 2010;65:528-33.
58. Islam LN, Nabi AH, Rahman MM, Zahid MS. Association of respiratory complications and elevated serum immunoglobulins with drinking water arsenic toxicity in human. J Environ Sci Health 2007;42:1807-14.
59. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271-7.
60. Hsu LI, Chen GS, Lee CH, Yang TY, Chen YH, Wang YH et al. Use of arsenic-induced palmoplantar hyperkeratosis and skin cancers to predict risk of subsequent internal malignancy. Am J Epidemiol 2013;177:202-12.